FADD expression as a prognosticator in early-stage glottic squamous cell carcinoma of the larynx treated primarily with radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages 1220-1226

  Schrijvers, Michiel L ^a   Pattje, Wouter J ^a   Slagter Menkema, Lorian ^a   Mastik, Mirjam F ^a   Gibcus, Johan H ^a   Langendijk, Johannes A ^a   Van Der Wal, Jacqueline E ^a   Van Der Laan, Bernard F A M ^a   Schuuring, E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

FADD; Larynx; Prognostic marker; Radiotherapy; Squamous cell carcinoma

Indexed keywords

AMPLICONS; CONFIDENCE INTERVAL; COX REGRESSION ANALYSIS; DISEASE-SPECIFIC SURVIVALS; EXPRESSION LEVELS; FADD; FAS-ASSOCIATED DEATH DOMAINS; GLOTTIC CARCINOMAS; HAZARD RATIO; IMMUNOHISTOCHEMICAL STAINING; ISOFORMS; LARYNGEAL CARCINOMAS; LARYNX; LOCAL CONTROL; OVER-EXPRESSION; PRE-TREATMENT; PROGNOSTIC MARKER; SQUAMOUS CELL CARCINOMA;

PESTICIDE EFFECTS; PHOSPHORYLATION; REGRESSION ANALYSIS; STATISTICS;

RADIOTHERAPY;

FAS ASSOCIATED DEATH DOMAIN PROTEIN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; LARYNX SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CORTACTIN; CYCLIN D1; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; GLOTTIS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862661277     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.09.060     Document Type: Article

References (20)

1. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: Cyclin D1 and EMS1 are two new candidate oncogenes - A review. Gene 1995;159:83-96.
2. Akervall JA, Jin Y, Wennerberg JP, et al. Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer 1995;76:853-859.
3. Gibcus JH, Menkema L, Mastik MF, et al. Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res 2007;13:6257-6266.
4. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-512.
5. Hua ZC, Sohn SJ, Kang C, Cado D, Winoto A. A function of Fas-associated death domain protein in cell cycle progression localized to a single amino acid at its C-terminal region. Immunity 2003;18:513-521.
6. Osborn SL, Sohn SJ, Winoto A. Constitutive phosphorylation mutation in Fas-associated death domain (FADD) results in early cell cycle defects. J Biol Chem 2007;282:22786-22792.
7. Alappat EC, Feig C, Boyerinas B, et al. Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell 2005;19:321-332.
8. Alappat EC, Volkland J, Peter ME. Cell cycle effects by C-FADD depend on its C-terminal phosphorylation site. J Biol Chem 2003;278:41585-41588.
9. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J Pathol 2005;206:423-432.
10. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:928-942.
11. Gibcus JH, Mastik MF, Menkema L, et al. Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer 2008;98:950-955.
12. Chen G, Bhojani MS, Heaford AC, et al. Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A 2005;102:12507-12512.
13. Schrijvers ML, van der Laan BF, de Bock GH, et al. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:161-169.
14. Coco Martin JM, Balkenende A, Verschoor T, Lallemand F, Michalides R. Cyclin D1 overexpression enhances radiation-induced apoptosis and radiosensitivity in a breast tumor cell line. Cancer Res 1999;59:1134-1140.
15. Yoo SS, Carter D, Turner BC, et al. Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Int J Cancer 2000;90:22-28.
16. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer 2004;100:1786-1792.
17. Xia F, Powell SN. The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin Radiat Oncol 2002;12:296-304.
18. Akervall JA, Michalides RJ, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997;79:380-389.
19. van Rossum AG, Moolenaar WH, Schuuring E. Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res 2006;312:1658-1670.
20. Morshed K, Skomra D, Korobowicz E, Szymanski M, Polz-Dacewicz M, Golabek W. An immunohistochemical study of cyclin D1 protein expression in laryngeal squamous cell carcinoma. Acta Otolaryngol 2007;127:760-769.